Yearly Archives: "2015"

Recent Posts

• CMSC Press Release – Kathleen Costello, CRNP, MSCN Appointed Interim CEO of the CMSC
• Press Release: New 48-Week Frexalimab Phase 2 Data Support Potential For High Sustained Efficacy In Multiple Sclerosis
• The Siegel Rare Neuroimmune Association Marks 30 Years of Improving Quality of Life for People With Rare Neuroimmune Disorders
• Best Practices Guideline on the Use of Neurofilament
• The Language of MS: How Much Does It Matter?
• Genentech’s Ocrevus Twice-Yearly, 10-Minute Subcutaneous Injection Was Non-Inferior to Intravenous Infusion and Provided Near-Complete Suppression of Brain Lesions
• Thinking Critically about World Wide Web Resources
• Is it MS or Something Else? updated guide is published to expedite and uncover the answer
• In memoriam: Barry GW Arnason, MD, FAAN
• Positive Phase III results for Genentech’s Ocrevus (ocrelizumab)